Market revenue in 2020 | USD 335.4 million |
Market revenue in 2028 | USD 981.2 million |
Growth rate | 14.4% (CAGR from 2020 to 2028) |
Largest segment | Topical |
Fastest growing segment | Injectable |
Historical data | 2017 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Topical, Injectable, Oral |
Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 36.46% in 2020. Horizon Databook has segmented the Canada atopic dermatitis drugs market based on topical, injectable, oral covering the revenue growth of each sub-segment from 2017 to 2028.
Canada is a rapidly developing market for atopic dermatitis. High prevalence of the disease and increasing consumer awareness in the country are expected to further boost the market. Atopic dermatitis affects 17% of the population at least once per lifetime.
This creates a large patient pool for prescription of atopic dermatitis drugs. The Eczema Society of Canada works to facilitate the treatment of eczema and atopic dermatitis patients. Furthermore, November is celebrated in Canada as Eczema Awareness Month, which aims to raise awareness about the disease and related conditions.
In November 2018, Pfizer announced the availability of EUCRISA (crisaborole) in Canada, intended to ease the treatment of atopic dermatitis patients. Novel biologic drug DUPIXENT by Sanofi was approved by Health Canada in September 2019, making it the first biologic drug approved for atopic dermatitis.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into Canada atopic dermatitis drugs market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account